Pyrazinamide (PZA) is one of the three most important drugs for treatment of Mycobacterium tuberculosis infections. The antibacterial activity of PZA requires a bacterial enzyme, pyrazinamidase (PZAase), which hydrolyzes PZA to form pyrazinoic acid and ammonia. Most PZA-resistant clinical M. tuberculosis isolates lack PZAase activity. With the goal of eventually identifying and characterizing the M. tuberculosis PZAase gene, we began with the more tractable organism, Escherichia coli, which also has PZAase activity. We screened a transposon-generated E. coli insertion mutant library, using a qualitative PZAase assay. Two PZAase-negative mutants out of 4,000 colonies screened were identified. In each mutant, the transposon interrupted the same 639-bp open reading frame (ORF), ORF1. The expression of ORF1 on a multicopy plasmid complemented a PZAase-negative mutant, leading to PZAase activity levels approximately 10-fold greater than those of the wild type. PZA has a structure similar to that of nicotinamide, a pyridine nucleotide cycle intermediate, so we tested our strains for nicotinamidase activity (EC 3.5.1.19) (genetic locus pncA). The construct with multiple plasmid copies of ORF1 had an approximately 10-fold increase in levels of nicotinamidase activity. This overexpressing strain could utilize nicotinamide as a sole nitrogen source, though wild-type E. coli cannot. We conclude that a single E. coli enzyme accounts for both PZAase and nicotinamidase activities and that ORF1 is the E. coli PZAase and nicotinamidase gene, pncA.
Pyrazinamide (PZA) is an important drug for the treatment of Mycobacterium tuberculosis infections. The addition of PZA to isoniazid (INH) and rifampin allowed the conventional 9-month tuberculosis treatment regimen to be shortened to 6 months (30) . These three drugs form the cornerstone of initial tuberculosis therapy as recommended by the Centers for Disease Control and Prevention (9) . PZA is also useful in the treatment of patients infected with multidrug-resistant M. tuberculosis strains (18) .
The precise mechanism of action of PZA is not known. A bacterial enzyme, pyrazinamidase (PZAase) (synonym, PZA amidohydrolase), is necessary for PZA activity (21) . PZAase hydrolyzes PZA to form pyrazinoic acid and ammonia (Fig. 1 ). M. tuberculosis strains which lose PZAase are uniformly resistant to PZA, and the loss of PZAase accounts for most PZAresistant clinical isolates (25) . As expected, pyrazinoic acid is active in vitro against both PZA-resistant and PZA-susceptible M. tuberculosis strains (21) ; its cellular target is not known.
PZA is structurally similar to nicotinamide (NAM), a pyridine nucleotide cycle intermediate (35) . Nicotinamidase (NAMase) (synonyms, NAM amidohydrolase and NAM deamidase) catalyzes a reaction very similar to that of PZAase ( Fig.  1 ) as a part of NAD recycling. The Escherichia coli NAMase gene (pncA) (synonym, nam) has been mapped to 39 min (4, 5, 10) . Circumstantial evidence suggests that a single M. tuberculosis enzyme has both PZAase and NAMase activities (21) . Although many bacteria produce PZAase (see data below), only members of the M. tuberculosis complex are known to be inhibited by PZA (16, 21) . The present study was directed at the identification of the E. coli PZAase gene, with the eventual goal of identifying the homologous gene in M. tuberculosis. In addition, E. coli may provide a model for understanding the mechanism of action of PZA. There are numerous advantages to working with E. coli (e.g., rapid growth, well-developed genetic tools, substantial sequence information). Several M. tuberculosis genes, including three genes responsible for drug resistance (8, 33, 40) , have been identified by using the sequences of their E. coli homologs. This report describes the identification, cloning, and expression of the E. coli PZAase gene.
MATERIALS AND METHODS
Strains and genetic elements. The E. coli strains and genetic elements used in this study are described in Table 1 Generation of an insertion mutant library. Derivative 103 of transposon Tn10 was delivered by using NK1316 to generate insertion mutants in E. coli N1624 (Table 1) (14, 20) . NK1316 contains a mutant transposase with a low specificity of insertion. The phage vector was lost after infection, because the phage has an amber mutation that is not suppressed by E. coli N1624. The integrated transposons are stable even in the absence of antibiotic selection, because the transposase gene is lost with the phage vector. The library was estimated to have about 10 6 independent members, and the vast majority should contain only a single transposon insert. Individual insertion mutant colonies were selected on LB agar (LB Agar, Miller; Difco Laboratories, Detroit, Mich.) with kanamycin (25 g/ml).
Qualitative PZAase assay for mycobacteria. The bulk of a large mycobacterial colony was transferred to the top of an agar butt containing PZA substrate as described by Wayne (37) . After 7 days of incubation, pyrazinoic acid product was detected by the formation of a red-colored complex with ferrous ammonium sulfate. The positive and negative controls were M. tuberculosis ATCC 25177 and M. bovis ATCC 35734, respectively (26) . Qualitative PZAase assay for E. coli and other gram-negative bacteria. Wayne's PZAase assay (37) was modified to screen the E. coli insertion mutant library. Each well of a 96-well microtiter plate was filled with 180 l of LB agar containing 4 mM PZA and inoculated from a single colony by stabbing with a sterile toothpick. After 2 or 3 days of incubation at 37ЊC, 100 l of 25 mM ferrous ammonium sulfate was added to each well to detect pyrazinoic acid product. Wild-type PZAase-positive E. coli colonies, which form an intense red color, were used as positive controls. Uninoculated wells (no red color) were used as negative controls until the first PZAase-negative E. coli mutant was identified (21C8). This strain served as the negative control in subsequent assays. The same assay was also used to test a variety of gram-negative bacteria, all of which grew well on LB agar except H. influenzae ATCC 10211. H. influenzae ATCC 10211 was tested by transferring the bulk of a large colony to a well filled with 1.5% (wt/vol) agar (Bacto-Agar; Difco) containing 4 mM PZA and comparing the pyrazinoic acid production after 3 days at 37ЊC to that of an E. coli colony of a similar size.
Quantitative E. coli PZAase assays. Each E. coli strain was grown overnight in LB broth (LB Broth, Miller; Difco) containing 8 mM PZA and appropriate antibiotics (kanamycin [25 g/ml] for the insertion mutants and ampicillin [500 g/ml] for the strain containing pEAST2). This ampicillin concentration is higher than that commonly used. The optical density at 600 nm (OD 600 ) was measured, and the samples were diluted to obtain OD measurements between 0.2 and 0.6. Bacteria were washed twice in assay buffer (150 mM NaCl, 100 mM TrisCl, pH 7.5) and then resuspended at an OD 600 of 40 (insertion mutants and wild-type strains) or 2 (strain containing pEAST2). Assays were performed both on whole cells and on a crude extract. The extract was generated by mixing 1.7 ml of bacterial suspension with 0.2 ml of glass beads (diameter, 25 to 50 m) and agitating the mixture at the highest speed in the MiniBeadbeater-8 (Biospec Products, Bartlesville, Okla.) for 30 s twice and 60 s once. Each agitation was separated by 2 min on ice. The glass beads were pelleted by centrifugation (2 min at 16,000 ϫ g at 4ЊC), washed with 0.3 ml of assay buffer, and centrifuged again. The two supernatants were combined as the crude extract. PZA substrate (8 mM final concentration) was added to each bacterial suspension or crude extract. Extracts were incubated at 37ЊC for 0, 15, 30, and 60 min. Bacterial suspensions were incubated at 37ЊC for 0, 15, 30, 60, and 120 min and then centrifuged for 3 min at 13,800 ϫ g at room temperature. Pyrazinoic acid product concentrations in the extracts and in the supernatants of the bacterial suspensions were determined by adding 0.05 volume of 500 mM ferrous ammonium sulfate and comparing the change in OD 480 with a standard curve. Samples were diluted as necessary to obtain an OD measurement between 0.2 and 1.0. PZAase activities were expressed as nanomoles of pyrazinoic acid produced per minute per OD 600 of bacterial cells. All enzyme determinations were performed at least three times with independently grown bacterial cultures.
PZAase production in the presence of potential effectors. E. coli N1624 was grown overnight in minimal medium M9 (3) and then was diluted 1/100 into fresh M9 and incubated in a shaker at 37ЊC. When the OD 600 was 0.1 to 0.4 (logarithmic growth phase), the culture was divided into eight aliquots. Two aliquots were kept as negative controls, and 10 mM (each) six potential effectors was added to the other aliquots. The aliquots were incubated for 2 h more and then centrifuged and assayed for PZAase activity by the quantitative assay described above. The experiment was repeated on four separate days.
Quantitative E. coli NAMase assay. The NAMase assay conditions were similar to those described above for PZAase. Bacterial suspensions were incubated in LB broth with either 0 or 8 mM NAM for 30, 60, 120, and 180 min. Ammonia product concentrations in the supernatants were determined with the Sigma ammonia diagnostic kit (Sigma Chemical Co., St. Louis, Mo.). We corrected for baseline ammonia production by subtracting the ammonia produced at each time point in cells incubated without NAM substrate.
Utilization of NAM as a sole nitrogen source. Minimal agar M63 was prepared with no (NH 4 ) 2 SO 4 and with 30 mM NAM as a nitrogen source, as described by Pardee et al. (27) . Appropriate antibiotics (kanamycin and/or ampicillin) were included. Overnight cultures of various strains of E. coli were spread on this agar, and growth was observed at 18 and 40 h.
Cloning transposon 103 with flanking DNA. Chromosomal DNA from E. coli 21C8 was purified, digested with various restriction enzymes, and ligated into the multiple cloning site of plasmid pSU18 ( Table 1 ). The ligation products were transformed into E. coli DH5␣ (Table 1) LB agar with 25 g of kanamycin per ml (transposon 103) and 25 g of chloramphenicol per ml (pSU18). PCR primers and conditions. Four primers were used in the PCR: M13R (5Ј AGCGGATAACAATTTCACACAGGA 3Ј), TRANSP (5Ј TGTTCCGTTGCG CTGCCCGG 3Ј), A (5Ј GAAGCCACGCTAACCAAACTGC 3Ј), and B (5Ј GCATCAATTGCCAGATGTGCC 3Ј). Primer M13R anneals at a location adjacent to the multiple cloning site of pSU18. Primer TRANSP is complementary to inverted repeat DNA about 100 bp from both ends of transposon 103. Primers A and B are complementary to E. coli chromosomal DNA about 100 bp upstream and downstream from pncA. About 5 ng of plasmid DNA or 5 l of bacterial lysate containing chromosomal DNA (13) was used in each 50-l reaction mixture. Multiple interspersed negative controls (reagents only, no DNA) were included each time that PCR was performed. For primer pair M13R ϩ TRANSP, the reaction mixture contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.01% (wt/vol) gelatin, 1.2 mM MgCl 2 , 100 nM each primer, 200 M (each) the four deoxynucleoside triphosphates, and 1.25 U of Taq DNA polymerase (Amplitaq DNA polymerase; Perkin-Elmer Cetus, Norwalk, Conn.) in a total volume of 50 l. The mixture was incubated at 95ЊC for 3 min, subjected to 25 temperature cycles (95ЊC for 1 min [denaturation], 55ЊC for 2 min [annealing], and 72ЊC for 1 min [extension]), incubated at 72ЊC for 10 min, and cooled to room temperature, all in the TwinBlock System TCX20A temperature cycler (Ericomp, San Diego, Calif.). For primer pairs TRANSP ϩ A, TRANSP ϩ B, and A ϩ B the reaction mixture had 2.0 mM MgCl 2 and no gelatin, but was otherwise identical to the mixture described above. The temperature cycles were also identical except that an annealing temperature of 60ЊC was used. The presence and size of each PCR product was determined by electrophoresis on an agarose gel containing ethidium bromide.
DNA sequencing and analysis. Plasmids and PCR products were sequenced directly with the Taq Dye Deoxy Terminator cycle sequencing kit and the 373A DNA Sequencer (both from Applied Biosystems, Foster City, Calif.) as previously described (12) . The computer program BLAST (2) was used to search the nucleotide and protein databases at the National Center for Biotechnology Information. GenBank nucleotide and protein accession numbers are M26934 and P21369, respectively (19) . Identification of the E. coli PZAase gene by insertion mutagenesis. A library of transposon insertion mutants in E. coli N1624 (PZAase positive) was screened for PZAase activity. By screening over 4,000 insertion mutants, two PZAase-negative mutants were identified (21C8 and 44D7). In order to identify the site of insertion, the transposon and adjoining chromosomal DNA were cloned into a recombinant plasmid, by using the kanamycin resistance gene of the transposon to select for the appropriate plasmid insert. An 8.4-kb EcoRI-SacI fragment of E. coli 21C8 chromosomal DNA, which contained transposon 103, was cloned in plasmid pSU18, generating plasmid pWAMO1 (Table 1) . Flanking DNA from one side of the transposon was isolated from pWAMO1 by PCR using the primer pair TRANSP ϩ M13R (Materials and Methods). The PCR product was sequenced directly by using the transposonspecific primer TRANSP, and the resulting sequence was used to search the National Center for Biotechnology Information databases. The site of transposon insertion in E. coli 21C8 was identified in the sequence with accession number M26934 and fell between the ribosomal binding site and start codon of open reading frame 1 (ORF1) (Fig. 2) . ORF1 is a 639-bp ORF with no known function. It is part of an operon with ansA, the gene for L-asparaginase I (Fig. 1) (19) .
RESULTS

Qualitative
Chromosomal DNA was then amplified to confirm the site of transposon insertion in E. coli 21C8 and to identify the site FIG. 2. Transposon insertion sites in two PZAase-negative insertion mutants. This figure includes the 3Ј end of the ansA gene and the complete 639-bp coding sequence of pncA (ORF1). The figure shows deduced amino acid sequences for both genes, sites for primers A and B, the pncA ribosomal binding site (RBS), and a region of hairpin symmetry which may terminate transcription (double underlined) (19) . The sites of transposon insertion in PZAase-negative mutants 21C8 and 44D7 are shaded. These insertion sites were determined by sequencing flanking DNA on both sides of the transposon in both strains. As expected, the transposon produced duplications of the 9-bp insertion site in each mutant (20) . Both transposon insertions interrupt translation of pncA. The figure includes nucleotides 1019 to 1859 from the GenBank sequence with accession number M26934 (19) , and the sequence is numbered from the start codon of pncA.
in E. coli 44D7. Chromosomal DNA from each strain was amplified with the transposon-specific primer TRANSP plus either primer A or B, which both anneal just outside the two ends of ORF1 (Fig. 2) . The PCR products from E. coli 21C8 (about 250 and 800 bp, respectively) and those from E. coli 44D7 (about 500 and 525 bp, respectively) were sequenced to determine the exact site of transposon insertion in each strain (Fig. 2) . Transposon insertion interrupted the translation of ORF1 in both PZAase-negative mutants. We have renamed ORF1 pncA on the basis of these results and those described below.
Cloning and expression of pncA. Chromosomal DNA from E. coli N1624 (PZAase positive) was amplified with primer pair A ϩ B (Fig. 2) , yielding the expected 841-bp product containing the 639-bp pncA gene with flanking DNA. This PCR product was ligated into plasmid pCRII (Table 1) with the TA cloning kit (Invitrogen, San Diego, Calif.). A resulting plasmid, pEAST2 (Table 1) , contained pncA in the correct orientation with respect to the plasmid lac promoter. The PZAase-negative insertion mutant E. coli 44D7 was transformed with pEAST2, converting its qualitative phenotype to PZAase positive.
Quantitative PZAase activities. Table 2 lists the qualitative and quantitative PZAase activities of the strains described above and those of an arbitrary insertion mutant strain, 15C5, with the wild-type phenotype (PZAase positive). Transposon insertion alone had no meaningful effect on PZAase production (compare whole-cell assay results for strains N1624 and 15C5). The two PZAase-negative insertion mutants (21C8 and 44D7) had no detectable PZAase activity in the whole-cell assay, representing at least a 40-fold reduction from wild-type levels. The plasmid pEAST2 restored the PZAase-positive phenotype to 44D7 and actually resulted in an approximately 10-fold-increased level of PZAase activity over wild-type levels. Overexpression was probably due to multiple plasmid copies and the strong plasmid lac promoter. The extracts had less PZAase activity than did the whole cells, but the same relative activities were observed. Plasmid pEAST2 also resulted in an approximately 10-fold increase in levels of PZAase activity when assayed in a crude extract, providing the strongest argument that the pncA gene is the structural gene for PZAase.
Quantitative NAMase activities. We tested the same strains for NAMase activities and found a similar pattern (Table 2) . Wild-type E. coli N1624 produces a low level of NAMase, similar to that found by previous investigators (27) . The PZAase-negative mutant 44D7 had no measurable NAMase activity. The plasmid construct 44D7 with pEAST expressing multiple copies of pncA had levels of NAMase activity that were about 10-fold increased over wild-type levels.
Utilization of NAM as sole nitrogen source. Ammonia is one of the products of NAMase and is also the preferred nitrogen source for E. coli (Fig. 1) . Wild-type E. coli does not produce enough NAMase to utilize NAM as a sole nitrogen source, but NAMase-hyperproducing mutants can use NAM as a sole nitrogen source (27) . We plated both 44D7 and 44D7 plus pEAST2 on minimal agar with 30 mM NAM as a sole nitrogen source. As expected, 44D7 (NAMase negative) did not grow but 44D7 with pEAST2 grew to confluence.
PZAase production in the presence of potential effectors. We grew E. coli N1624 for 2 h in minimal media with 10 mM (each) six potential effectors (L-asparagine, L-aspartic acid, PZA, pyrazinoic acid, NAM, and nicotinic acid.). These are the substrates and products of the three enzymatic activities attributed to the ansA-pncA operon, namely, L-asparaginase, encoded by ansA, and PZAase and NAMase, encoded by pncA (Fig. 1) . None of these compounds inhibited the growth of this E. coli strain under the conditions of the assay. We found no meaningful change in PZAase activity in the presence of any potential effector. The effectors and relative enzyme activities (mean Ϯ standard deviation), based on quadruplicate determinations, were as follows: no effector, 1.00 Ϯ 0.04; L-asparagine, 0.97 Ϯ 0.24; L-aspartic acid, 1.06 Ϯ 0.24; PZA, 0.93 Ϯ 0.07; pyrazinoic acid, 0.76 Ϯ 0.09; NAM, 1.06 Ϯ 0.12; and nicotinic acid, 0.88 Ϯ 0.12.
Comparison of PncA sequence with those in National Center for Biotechnology Information databases. The pncA nucleotide and PncA deduced amino acid sequences were used to search the National Center for Biotechnology Information databases. The search included the complete nucleotide sequence of PZAase-negative H. influenzae (accession number, L42023), and the available nucleotide sequences of Mycobacterium leprae (about 30% of the entire genome). Four proteins with significant similarity to PncA were found, and all were similar in the same region (PncA amino acids 132 to 170). Three of these are hypothetical Bacillus subtilis and E. coli proteins with no known function (accession numbers, P37532, P21367, and P37347). The fourth protein is the N-carbamoylsarcosine amidohydrolase (Fig. 1) of an Arthrobacter species (28) (accession number, P32400). The conserved regions of E. coli PncA and the four related proteins are aligned in Fig. 3 . The probable active site of the Arthrobacter N-carbamoylsarcosine amidohydrolase (cysteine 177) is in this conserved region and is itself conserved in PncA (cysteine 156) and in two of the three hypothetical proteins. Translation of pncA was interrupted before the cysteine 156 codon in both PZAasenegative insertion mutants (21C8 and 44D7).
DISCUSSION
E. coli pncA. We conclude that a single E. coli enzyme accounts for both PZAase and NAMase activities and that ORF1 is the E. coli PZAase and NAMase gene (pncA) on the basis of the following evidence. (i) Two of two PZAase-negative inser- VOL. 40, 1996 PYRAZINAMIDASE GENE 1429
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(ii) Expression of pncA on a multicopy plasmid complemented a PZAase-and NAMase-negative mutant, resulting in levels of PZAase and NAMase activity about 10-fold increased over wild-type levels. Importantly, increased PZAase activity was detected in crude extracts, eliminating the possibility that the increased activity was due to changes in the permeability of the substrate or the product. (iii) The construct with multiple plasmid copies of pncA was able to grow with NAM as a sole nitrogen source. (iv) The E. coli NAMase gene was previously mapped to 39 min, the same location as pncA (4, 5, 10, 19) . (v) The deduced PncA amino acid sequence has a region similar to the active site of a known amidohydrolase. PZAase and NAMase catalyze very similar reactions ( Fig.  1) , so it is not surprising to find that the same E. coli enzyme has both activities. NAMase is probably the natural function of PncA (27) , as PZA is not known to occur in nature. A single M. tuberculosis enzyme may also have both PZAase and NAMase activities (21) . Although it is unlikely, we did not exclude the possibility that E. coli pncA is a positive regulator of a separate gene or genes encoding PZAase and NAMase.
Operon organization. ansA (coding for L-asparaginase I) and pncA (coding for NAMase) form an operon. Both genes are transcribed from a common promoter upstream from ansA (19) , and a likely transcriptional terminator follows pncA. L-Asparaginase I and NAMase catalyze similar reactions (Fig.  1) . Their respective products are part of known pathways for NAD synthesis (aspartic acid) and cycling (nicotinic acid) (35) . The two genes do not appear to be products of gene duplication, since there is no meaningful homology between the DNA sequences of ansA and pncA or between their deduced amino acid sequences.
Both L-asparaginase I and NAMase are considered to be constitutive enzymes in E. coli (19, 27) . Pardee et al. (27) added various nicotinic acid derivatives to minimal media and found no effect on NAMase production. In a similar experiment, we tested six potential effectors (the substrates and products of L-asparaginase I, NAMase, and PZAase) and found no change in PZAase activity. Our results are consistent with the constitutive production of PZAase, though it is possible that these substances might influence PZAase production under different growth conditions (e.g., in a chemostat, on different media) or that other substances are effectors.
Implications for M. tuberculosis. M. tuberculosis normally loses its PZAase activity when it acquires PZA resistance. The loss of an enzyme activity is a relatively rare mechanism for the acquisition of drug resistance. Nonetheless, M. tuberculosis also develops resistance to INH by a similar mechanism, namely the loss of catalase activity (40) . (33) . Mutations in this region are associated with rifampin resistance in both species.
In a similar fashion, we are pursuing several strategies to identify the M. tuberculosis PZAase gene on the basis of the E. coli PZAase sequence. PZA-resistant PZAase-negative M. tuberculosis strains are likely to have PZAase gene mutations. The detection of those mutations may provide a rapid assay for PZA resistance in M. tuberculosis. Similar rapid molecular assays for rifampin resistance in M. tuberculosis have been developed (34, 38) . Rapid susceptibility testing for PZA and other antibiotics would allow early appropriate antibiotic therapy. Patients with multidrug-resistant M. tuberculosis who receive active drugs within 2 weeks of diagnosis have reduced mortality (11, 36) . Unfortunately, drug susceptibility testing for M. tuberculosis often takes more than 4 weeks (17) .
Potential application to M. bovis BCG. M. bovis BCG is a live vaccine given to infants to prevent tuberculosis. BCG is PZAase negative and PZA resistant, as are essentially all M. bovis strains (26) . Complications of BCG vaccination are rare, but disseminated infections and fatalities do occur. Lotte et al. (22, 23) gathered case reports of 39 cases of fatal disseminated BCG disease, and at least 20 additional fatal cases have been reported since those reviews. Fatalities have been caused by BCG strains with acquired resistance to multiple drugs (24, 29) . An ideal live tuberculosis vaccine should be susceptible to all first-line drugs, including PZA. We are currently attempting to express the E. coli pncA gene in M. bovis BCG with the goal of making BCG sensitive to PZA. In a similar fashion, expression of katG restores INH sensitivity in INH-resistant M. tuberculosis isolates (39) . Work is under way to construct a recombinant BCG strain expressing multiple vaccine antigens FIG. 3 . Alignment of partial amino acid sequences of E. coli PncA (PZAase) and related proteins. Related proteins include an Arthrobacter species carbamoylsarcosine amidohydrolase (CSHase) and hypothetical proteins from B. subtilis and E. coli. The beginning and ending amino acid positions of these segments are indicated, and the latter is followed by the total number of amino acids in each protein sequence. Each sequence is compared with the E. coli PncA sequence. Identical amino acids are indicated by two dots, and similar amino acids are indicated by one dot. The following amino acids are defined as similar: A, S, and T; D and E; N and Q; R and K; I, L, M, and V; and F, Y, and W. The probable active site of the Arthrobacter amidase, cysteine 177 (28) , is shaded as are the corresponding residues in the other proteins. This cysteine is conserved in PncA and in two of the three other protein sequences shown. (32) . The inclusion of pncA or other antibiotic susceptibility genes might enhance the safety of this vaccine.
